This segment focuses on the research, development, and commercialization of innovative therapies to combat infectious diseases. Shionogi's activities include the development of antibacterial agents, antiviral drugs, and vaccines. Key products include Fetroja for treating multidrug-resistant gram-negative bacterial infections and Xofluza for influenza. Research and development efforts involve identifying novel drug targets, conducting preclinical and clinical trials, and securing regulatory approvals. The company utilizes advanced technologies such as structure-based drug design and high-throughput screening to discover new drug candidates. Patient impact is significant, as these therapies address critical unmet medical needs and improve patient outcomes. Market positioning is strong, with a focus on addressing emerging infectious disease threats. Future opportunities include expanding the product portfolio and geographic reach. Regulatory aspects involve navigating complex approval processes in various countries, and collaborations with research institutions and global health organizations are crucial for advancing research and access to medicines.

This segment is dedicated to the development and commercialization of therapies for the treatment of Human Immunodeficiency Virus (HIV). Shionogi's primary focus is on providing effective and accessible treatments to improve the lives of individuals living with HIV. The company's activities include research and development of antiretroviral drugs, clinical trials to assess safety and efficacy, and manufacturing and distribution of approved medications. Tivicay is a key product in this segment. Research and development efforts involve exploring new drug targets, developing novel drug formulations, and conducting clinical studies to evaluate treatment regimens. The company utilizes advanced technologies such as molecular modeling and drug delivery systems to optimize drug efficacy and patient outcomes. Patient impact is substantial, as these therapies help to control the virus, prevent disease progression, and improve the quality of life for people with HIV. Market positioning is competitive, with a focus on providing innovative and cost-effective treatment options. Future opportunities include expanding the product portfolio, developing long-acting formulations, and addressing emerging challenges in HIV treatment. Regulatory aspects involve obtaining approvals from health authorities worldwide, and collaborations with healthcare providers and patient advocacy groups are essential for ensuring access to treatment.

This segment focuses on the research, development, and commercialization of therapies for the treatment of various types of pain, including inflammatory, neuropathic, and chronic pain conditions. Shionogi's activities include the discovery and development of novel analgesic agents, clinical trials to assess safety and efficacy, and manufacturing and distribution of approved medications. The company is developing several compounds for pain management, including S-120083 for inflammatory pain, S-010887 and sivopixant for neuropathic pain, and S-637880 for neuropathic low back pain. Research and development efforts involve identifying novel drug targets, conducting preclinical and clinical trials, and securing regulatory approvals. The company utilizes advanced technologies such as high-throughput screening, molecular modeling, and advanced imaging techniques to discover and develop new drug candidates. Patient impact is significant, as these therapies aim to alleviate pain, improve quality of life, and reduce the burden of chronic pain conditions. Market positioning is competitive, with a focus on providing effective and safe pain management solutions. Future opportunities include expanding the product portfolio, developing personalized pain management strategies, and addressing unmet needs in chronic pain treatment. Regulatory aspects involve obtaining approvals from health authorities worldwide, and collaborations with pain specialists and patient advocacy groups are essential for ensuring access to treatment.

This segment is dedicated to the research, development, and commercialization of therapies for central nervous system (CNS) disorders, including depression, insomnia, and attention-deficit/hyperactivity disorder (ADHD). Shionogi's activities include the discovery and development of novel CNS drugs, clinical trials to assess safety and efficacy, and manufacturing and distribution of approved medications. Key products and development candidates include Zuranolone for depression, S-117957 for insomnia, and SDT-001 for ADHD. Research and development efforts involve identifying novel drug targets, conducting preclinical and clinical trials, and securing regulatory approvals. The company utilizes advanced technologies such as neuroimaging, molecular biology, and behavioral assessments to discover and develop new drug candidates. Patient impact is substantial, as these therapies aim to alleviate symptoms, improve cognitive function, and enhance the quality of life for individuals with CNS disorders. Market positioning is competitive, with a focus on providing innovative and effective treatment options. Future opportunities include expanding the product portfolio, developing personalized treatment approaches, and addressing unmet needs in CNS disorders. Regulatory aspects involve obtaining approvals from health authorities worldwide, and collaborations with neurologists, psychiatrists, and patient advocacy groups are essential for ensuring access to treatment.